Needle-free injection of basal insulin improves fasting glucose variability as assessed by continuous glucose monitoring in T2DM: a prospective randomized multicenter open-label crossover study

References

• Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014Aug;378:2359–2365. PubMed PMID: 24812434; eng
   PubMed Web of Science ®Google Scholar
• Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). PubMed PMID: 28913575; PubMed Central PMCID: PMCPMC6002963, Diabetologia. 2018 Jan;61(1):48–57.
   PubMed Web of Science ®Google Scholar
• Zhou JJ, Koska J, Bahn G, et al. Fasting glucose variation predicts microvascular risk in ACCORD and VADT. J Clin Endocrinol Metab. 2021 Mar 25;106(4):1150–1162. PubMed PMID: 33367811; PubMed Central PMCID: PMCPMC7993576. eng.
   PubMed Web of Science ®Google Scholar
• DeVries JH, Bailey TS, Bhargava A, et al. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: a post hoc analysis of the SWITCH Trials. Diabetes Obes Metab. 2019Mar;213:622–630. PubMed PMID: 30362250; PubMed Central PMCID: PMCPMC6587774. eng
   PubMed Web of Science ®Google Scholar
• Yang CP, Lin CC, Li CI, et al. Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes. Cardiovasc Diabetol. 2020 Jan 7;19(1):4. PubMed PMID: 31910828; PubMed Central PMCID: PMCPMC6945758. eng.
   PubMed Web of Science ®Google Scholar
• Hsieh YT, Hsieh MC. Fasting plasma glucose variability is an independent risk factor for diabetic retinopathy and diabetic macular oedema in type 2 diabetes: an 8-year prospective cohort study. Clin Exp Ophthalmol. 2020May;48(4):470–476. PubMed PMID: 32065699; eng.
   PubMed Web of Science ®Google Scholar
• Yang W, Ma J, Yuan G, et al. Determining the optimal fasting glucose target for patients with type 2 diabetes: results of the multicentre, open-label, randomized-controlled FPG GOAL trial. Diabetes Obes Metab. 2019Aug;218:1973–1977. PubMed PMID: 30938035; PubMed Central PMCID: PMCPMC6772047. eng
   PubMed Web of Science ®Google Scholar
• Yuan L, Li F, Zhou Y, et al. Fasting glucose of 6.1 mmol/L as a possible optimal target for type 2 diabetic patients with insulin glargine: a randomized clinical trial. J Diabetes Res. 2021;2021:5524313. PubMed PMID: 34337072; PubMed Central PMCID: PMCPMC8294995. eng.
   PubMed Web of Science ®Google Scholar
• Salti I. Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan. Diabet Med. 2009Dec;26(12):1255–1261. PubMed PMID: 20002478; eng.
   PubMed Web of Science ®Google Scholar
• Bremseth DL, Pass F. Delivery of insulin by jet injection: recent observations.Diabetes Technol Ther.2001;3(2):225–232; Summer;():. PubMed PMID: 11478329; eng;
   PubMedGoogle Scholar
• Pan Q, Zhang L, Gu A, et al. The absorption of needle-free insulin aspart through jet injector in different body parts of healthy individuals. Front Endocrinol (Lausanne). 2022;13:832726. PubMed PMID: 35574009; PubMed Central PMCID: PMCPMC9099202. eng.
   PubMed Web of Science ®Google Scholar
• Engwerda EE, Abbink EJ, Tack CJ, et al. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care. 2011 Aug;34(8):1804–1808. PubMed PMID: 21715522; PubMed Central PMCID: PMCPMC3142054. eng.
   PubMed Web of Science ®Google Scholar
• Engwerda EE, Tack CJ, de Galan BE. Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. Diabetes Care. 2013Nov;36(11):3436–3441. PubMed PMID: 24089542; PubMed Central PMCID: PMCPMC3816925. eng.
   PubMed Web of Science ®Google Scholar
• Xing Y, Xie X, Xu J, et al. Efficacy and safety of a needle-free injector in Chinese patients with type 2 diabetes mellitus treated with basal insulin: a multicentre, prospective, randomised, crossover study. PubMed PMID: 31359813, Expert Opin Drug Deliv. 2019 Sep;16(9):995–1002.
   PubMed Web of Science ®Google Scholar
• Kong X, Luo M, Cai L, et al. Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system. PubMed PMID: 33317342, Expert Opin Drug Deliv. 2021 May;18(5):635–641.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang J, Li H, et al. Comparison of glucose variability in patients with type 2 diabetes administrated glargine with needle-free jet injector and conventional insulin pen. PubMed PMID: 32141347, Expert Opin Drug Deliv. 2020 May;17(5):713–717.
   PubMed Web of Science ®Google Scholar
• Wittmann A, Köver J, Kralj N, et al. Insulin leakage value in relation to pen needle length and administered dose after subcutaneous injection. Diabetes Technol Ther. 2010Aug;128:587–590. PubMed PMID: 20615098; eng
   PubMed Web of Science ®Google Scholar
• Hofman PL, Derraik JG, Pinto TE, et al. Defining the ideal injection techniques when using 5-mm needles in children and adults. Diabetes Care. 2010Sep;339:1940–1944. PubMed PMID: 20585002; PubMed Central PMCID: PMCPMC2928337. eng
   PubMed Web of Science ®Google Scholar
• Kreugel G, Keers JC, Kerstens MN, et al. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther. 2011Jul;137:737–741. PubMed PMID: 21476936; PubMed Central PMCID: PMCPMC3118929. eng
   PubMed Web of Science ®Google Scholar
• Varghese JS, Ho JC, Anjana RM, et al. Profiles of intraday glucose in type 2 diabetes and their association with complications: an analysis of continuous glucose monitoring data. Diabetes Technol Ther. 2021Aug;238:555–564. PubMed PMID: 33720761; eng
   PubMed Web of Science ®Google Scholar
• Matsutani D, Sakamoto M, Iuchi H, et al. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2018 Mar 7;17(1):36. PubMed PMID: 29514695; PubMed Central PMCID: PMCPMC5840775.
   PubMedGoogle Scholar
• Jun JE, Jin SM, Baek J, et al. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol. 2015 Jun 4;14:70. PubMed PMID: 26041130; PubMed Central PMCID: PMCPMC4462181. eng.
   PubMed Web of Science ®Google Scholar
• Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. PubMed PMID: 10857967; eng, Diabetes Care. 2000 Jan;23(1):45–50.
   PubMed Web of Science ®Google Scholar
• Lee CL, Sheu WH, Lee IT, et al. Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes. Diabetes Metab. 2018Mar;442:121–128. PubMed PMID: 29032950; eng
   PubMed Web of Science ®Google Scholar
• Foreman YD, Brouwers M, van der Kallen CJH, et al. Glucose variability assessed with continuous glucose monitoring: reliability, reference values, and correlations with established glycemic indices-the maastricht study. Diabetes Technol Ther. 2020May;225:395–403. PubMed PMID: 31886732; eng
   PubMed Web of Science ®Google Scholar
• Mu P, Lu H, Zhang G, et al. Comparison of fasting capillary glucose variability between insulin glargine and NPH. Diabetes Res Clin Pract. 2011Jan;911:e4–7. PubMed PMID: 20970870
   PubMed Web of Science ®Google Scholar
• Ling J, Poon EWM, Yang A, et al. Glycemic variability and time in range during self-titration of once daily insulin Glargine 300 U/ml versus neutral protamine hagedorn insulin in insulin-naive Chinese type 2 diabetes patients. Diabetes Ther. 2021May;125:1399–1413. PubMed PMID: 33738774; PubMed Central PMCID: PMCPMC8099948
   PubMed Web of Science ®Google Scholar
• Scholtz HE, Pretorius SG, Wessels DH, et al. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005Oct;4810:1988–1995. PubMed PMID: 16160867
   PubMed Web of Science ®Google Scholar
• Porcellati F, Bolli GB, Fanelli CG. Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther. 2011Jun; 13 Suppl 1: S15–24 PubMed PMID: 21668333
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004Jun;536:1614–1620. PubMed PMID: 15161770; eng
   PubMed Web of Science ®Google Scholar
• Hirsch LJ, Gibney MA, Albanese J, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm  ×  32G insulin pen needle in adults with diabetes. Curr Med Res Opin. 2010Jun;266:1531–1541. PubMed PMID: 20429832; eng
   PubMed Web of Science ®Google Scholar
• Præstmark KA, Stallknecht B, Jensen ML, et al. Injection technique and pen needle design affect leakage from skin after subcutaneous injections. J Diabetes Sci Technol. 2016Jul;10 4:914–922. PubMed PMID: 26798083; PubMed Central PMCID: PMCPMC4928216. eng
   PubMedGoogle Scholar
• Siegmund T, Blankenfeld H, Schumm-Draeger P-M. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: “thin-wall” needles compared to “regular-wall” needles: an open-label study. Diabetes Technol Ther. 2009Aug;11(8):523–528. PubMed PMID: 19698066; eng.
   PubMed Web of Science ®Google Scholar
• Malone JI, Lowitt S, Grove NP, et al. Comparison of insulin levels after injection by jet stream and disposable insulin syringe. Diabetes Care. 1986Nov-Dec;96:637–640. PubMed PMID: 3542456; eng
   PubMed Web of Science ®Google Scholar